Aerie Pharmaceuticals Company Profile (NASDAQ:AERI)

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.84) by $0.02. View Aerie Pharmaceuticals' Earnings History.

12 equities research analysts have issued twelve-month price targets for Aerie Pharmaceuticals' shares. Their predictions range from $48.00 to $100.00. On average, they anticipate Aerie Pharmaceuticals' stock price to reach $69.17 in the next year. View Analyst Ratings for Aerie Pharmaceuticals.

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:

• 1. Mizuho analysts commented, "We expect an approval on or prior to the PDUFA date." (10/16/2017)
• 2. According to Zacks Investment Research, "Aerie’s efforts on developing two late-stage candidates – Rhopressa and Roclatan – are encouraging. However, with no approved product in its portfolio, Aerie depends heavily on a potential approval of Rhopressa. The company resubmitted new drug application (NDA) for lead candidate Rhopressa in Feb 2017. The FDA determined that the application is sufficiently complete to permit a substantive review and set the PDUFA goal date for the completion of review as Feb 28, 2018. A further delay will impact the growth prospects. A meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA has been scheduled for October 13 to review the NDA. A potential approval of Rhopressa in early 2018 and successful commercialization will significantly boost the company’s growth prospects in the global ophthalmic market. Aerie’s shares performed worse than the industry in the last three months." (10/10/2017)
• 3. HC Wainwright analysts commented, "Blueprint reported a Q1 net loss of $28MM and ended the quarter with $452MM." (5/3/2017)
• 4. Aegis analysts commented, "We still consider the upcoming Mercury 2 three-month efficacy readout for Roclatan expected before the end of Q2, 2017 as being a potentially share moving event. Higher patients dropout rate seen in Rhopressa arm relative to Timolol arm is not concerning to us. 30% of the patients in the Rhopressa arm of the trial discontinued treatment by month 6 compared to 12% of the patient population in the Timolol arm. The most common reason for discontinuation seen in the Rhopressa arm was related to adverse events, at about 19.4%. 2.2% (8) of the subjects in the Timolol arm dropped out due to adverse events. As a point of reference, given that 47% of patients (118 out of 251 patients) on Rhopressa QD completed the treatment by month 12 in Rocket 2, we estimate a maximum drop-off rate of Rhopressa at 53%. Further, according to results published in Persistency: A New Take on Patient Care" by Schwartz in Review of Ophthalmology 11.4 (2004): 108, the discontinuation rates of 66%/50%/46% for Latanoprost/Travoprost/Bimatoprost were seen at month 3 and 6, with rates increasing to 67%/81%/81%, respectively, at month 12." (4/13/2017)
• 5. Needham & Company LLC analysts commented, " AERI reported 4Q16 financials and updated ongoing Rhopressa and Roclatan development activities. The Rhopressa NDA was refiled in late Feb following an issue at the third party manufacturer. AERI expects a potential PDUFA in 1Q18 after a standard FDA review and is in the process of building a commercial org in anticipation of a 1H18 product launch. Key data from both Rhopressa and Roclatan are expected in 2Q17: top-line safety data from the ph 3 ROCKET-4 trial and top-line efficacy data from the ph 3 MERCURY-2 trial. AERI expects to file an NDA for Roclatan in late 2017/early 2018. We maintain our Buy rating and slightly adjust our $PT to $58 (from $52) to reflect a model and valuation update." (3/8/2017)

Some companies that are related to Aerie Pharmaceuticals include Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Sarepta Therapeutics (SRPT), AveXis (AVXS), Spark Therapeutics (ONCE), GW Pharmaceuticals PLC (GWPH), Halozyme Therapeutics (HALO), Prothena Corporation PLC (PRTA), Loxo Oncology (LOXO), Array BioPharma (ARRY), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Acceleron Pharma (XLRN), NovoCure Limited (NVCR) and Radius Health (RDUS).

Aerie Pharmaceuticals' management team includes the folowing people:

• Vicente Anido Jr., Ph.D., Chairman of the Board, Chief Executive Officer
• Thomas A. Mitro, President, Chief Operating Officer
• Casey C. Kopczynski Ph.D., Co-Founder, Chief Scientific Officer
• Richard J. Rubino CPA, Chief Financial Officer, Secretary
• Deanne F. Melloy, Vice President - Marketing
• Tori Arens, Vice President - Drug Product Manufacturing
• Eric Carlson, Vice President - Research & Development
• Gerald D. Cagle Ph.D., Independent Director
• Richard J. Croarkin, Independent Director
• Michael M. Du Toit, Independent Director

Shares of Aerie Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Aerie Pharmaceuticals stock can currently be purchased for approximately $65.10.